ODYSSEY FH i and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

European Heart Journal

Volumn 36, Issue 43, 2015, Pages 2996-3003

  Kastelein, John J P ^a   Ginsberg, Henry N ^b   Langslet, Gisle ^c   Kees Hovingh, G ^a   Ceska, Richard ^d   Dufour, Robert ^e   Blom, Dirk ^f   Civeira, Fernando ^g   Krempf, Michel ^h   Lorenzato, Christelle ⁱ   Zhao, Jian ^j   Pordy, Robert ^j   Baccara Dinet, Marie T ⁱ   Gipe, Daniel A ^j   Geiger, Mary Jane ^j   Farnier, Michel ^k  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CHARLES UNIVERSITY   (Czech Republic)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ SANOFI   (France)

^j REGENERON PHARMACEUTICALS INC   (United States)

^k Point Medical ^*  (France)

more..

Author keywords

Alirocumab PCSK9 Heterozygous familial hypercholesterolaemia Cardiovascular risk LDL C

Indexed keywords

ALANINE AMINOTRANSFERASE; ALIROCUMAB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISORDERS OF HIGHER CEREBRAL FUNCTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EYE DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE REACTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MYALGIA; NEUROLOGIC DISEASE; NON SMALL CELL LUNG CANCER; OGILVIE SYNDROME; PANCREAS CANCER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SINUSITIS; SUDDEN CARDIAC DEATH; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84983160332     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv370     Document Type: Article

References (18)

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A. Familial hyper-cholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-3490a.
2. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303:893-896.
3. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999;142:105-112.
4. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, Hutten BA. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010;5:e9220.
5. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF, Visseren FL. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010;209:189-194.
6. Seidah NG, Awan Z, Chretien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res 2014;114:1022-1036.
7. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect ofamonoclonal antibodytoPCSK9, REGN727/SAR236553, toreduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterol-aemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
8. Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther 2014;28:281-289.
9. Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
10. Mol MJ, Erkelens DW, Leuven JA, Schouten JA, Stalenhoef AF. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet 1986;2: 936-939.
11. Kastelein JJ. Decade in review-dyslipidaemia: resurgence of targets and compounds to treat dyslipidaemia. Nat Rev Cardiol 2014;11:629-631.
12. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366: 1108-1118.
13. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the PCSK9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J 2015;169:906-915.e13.
14. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015; 36:1186-1194.
15. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;16:1489-1499.
16. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014; 35:2249-2259.
17. Alonso R, Andres E, Mata N, Fuentes-Jimenez F, Badimon L, Lopez-Miranda J, Padro T, Muniz O, Diaz-Diaz JL, Mauri M, Ordovas JM, Mata P. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014;63: 1982-1989.
18. Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. Effect of alirocumab, a monoclonal propro-tein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Car-diol 2014;114:711-715.